Journal of Clinical Microbiology and Antimicrobials

OPEN ACCESS Freely available online

Commentary

The Off-Target Selection Plays a Role in Daptomycin Resistance in *Enterococcus faecium*

Scott Dave*

Departments of Infectious Diseases and Pediatrics, University of Otago, Dunedin, New Zealand

DESCRIPTION

Antibiotic resistance is a growing problem in healthcare, and despite extensive intervention efforts, the issue persists. One possible solution to this problem is to conduct thorough research on the population dynamics that cause resistance. Off-target selection of bacterial populations that are outside the intended targets of antimicrobial therapy can be a significant cause of resistance in the most alarming antibiotic-resistant diseases. It focuses on the significant nosocomial pathogen *Enterococcus faecium* in a hospital system where daptomycin resistance is developing despite conventional treatments. The study states that intravenous daptomycin usage results in off-target selection for resistance in *E. faecium* populations in the gastrointestinal tract that are transmittable.

To test this hypothesis, a case-control research was conducted, and the daptomycin resistance of *E. faecium* was compared between a control group of individuals treated with linezolid, a medication with comparable indications, and the faecium recovered from rectal swabs from patients who had been exposed to daptomycin. The results showed that the daptomycin resistance of *E. faecium* from the off-target population was, on average, 50% greater in the daptomycin-exposed group than it was in the control group. Among individuals who had been exposed to daptomycin, there was also more phenotypic variation in daptomycin resistance.

A minority of patients had access to many samples taken over time, and these samples show a wide range in temporal dynamics, from the quick restoration to sensitivity after stopping daptomycin medication to the long-term preservation of resistance. Study findings show that gastrointestinal populations that are off-target react quickly to intravenous antibiotic administration. The source of faecal transmission is the gastrointestinal population, which can also be the cause of rises in resistance at the population level across the hospital [1].

Antimicrobial therapy causes antimicrobial resistance to develop and spread. Suppressing population growth has the unavoidable side effect of selective pressure favoring resistance for the microbial population that is the focus of medication therapy. Antimicrobial exposure, however, is not restricted to the site of infection and can thus impose pressure on populations who are considered to be off-target or bystanders. For colonizing opportunistic infections, which include the multidrug-resistant pathogens of greatest concern, this off-target selection pressure is particularly troublesome [2-4]. No therapeutic advantages may be derived by applying antimicrobial pressure to these colonizing organisms, but it can favor antibiotic-resistant infections in the treated patient or the spread of resistant isolates to uninfected individuals.

Many opportunistic infections, including Enterobacteriaceae, have shown evidence of selection for resistance in populations of gastrointestinal carriers. Bacteroides and Enterococcus Selection on non-target groups may frequently have a significant role in population level resistance. For instance, it has been calculated that up to 90% of the medication exposure that Klebsiella experiences is off-target. It is difficult to understand the evolutionary dynamics in these populations that are off-target. The evaluation of novel resistance management strategies in the off-target population, such as the selection of an antimicrobial spectrum, the use of antibiotic combinations, optimized routes of administration, and the addition of novel adjuvant therapies, is hampered by this fundamental knowledge gap [5].

A number of studies have also indicated that having received past daptomycin therapy is a significant risk factor for infection with daptomycin-resistant Vancomycin Resistant Enterococci (VRE), which is consistent with off-target selection. The prevalence of transfer faecium in hospital settings means that any resistance that develops in one patient might endanger other patients [6]. After stopping daptomycin therapy, the maintenance of resistance varies greatly amongst patients. Those in whom a second sample was taken following the completion of therapy.

In summary, the article discusses the problem of antibiotic resistance and the potential solution of researching population dynamics that cause resistance. The focus is on *Enterococcus faecium*, a significant nosocomial pathogen in a hospital system where daptomycin resistance is developing despite conventional treatments. The article presents the hypothesis that intravenous daptomycin usage results in off-target selection for resistance in

Correspondence to: Scott Dave, Departments of Infectious Diseases and Pediatrics, University of Otago, Dunedin, New Zealand, E-mail: daves@qut.edu.nz

Received: 01-Mar-2023, Manuscript No. JCMA-23-22418; **Editor assigned:** 03-Mar-2023, Pre QC No: JCMA-23-22418 (PQ); **Reviewed:** 17-Mar-2023, QC No: JCMA-23-22418; **Revised:** 24-Mar-2023, Manuscript No: JCMA-23-22418 (R); **Published:** 31-Mar-2023,DOI:10.35248/JCMA. 23.7.143

Citation: Dave S (2023) The Off-Target Selection Plays a Role in Daptomycin Resistance in *Enterococcus faecium*. J Clin Microbiol Antimicrob. 7:143.

E. faecium populations in the gastrointestinal tract that are transmittable. The results of a case-control study support this hypothesis, showing that the daptomycin resistance of *E. faecium* from the off-target population was 50% greater in the daptomycin-exposed group than it was in the control group. The article emphasizes the importance of understanding the evolutionary dynamics in these off-target populations and the need for novel resistance management strategies. The findings also highlight the potential danger of resistance spreading to other patients through fecal transmission in hospital settings.

REFERENCES

1. Hampton T. Report reveals scope of US antibiotic resistance threat. JAMA. 2013;310:1661–1663.
2. Chuanchuen R, Karkhoff-Schweizer R R, Schweizer H P, High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect. Control. 2003;31:124-127.
3. Principe L, Capone A, Mazzarelli A, Arezzo D S, Bordi E, Caro D A, et al. *In vitro* activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb Drug Resist. 2013;19:407-414.
4. Fernández L, Hancock R E W. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012;25:661-681.
5. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs. 2003;12:379-399.
6. Allen H K, Moe L A, Rodbumrer J, Gaarder A, Handelsman J. Functional metagenomics reveals diverse β-lactamases in a remote Alaskan soil. ISME J. 2009;3:243-251.